Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 déc. 2015 06h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces Results From the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients With End Stage Renal Disease

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for...
06 déc. 2015 09h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL), a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System (CNS)

Overall Response Rate >70% and no GvHD Observed in Patients with Refractory CMV Chorioretinitis or Meningoencephalitis Findings Reported at American Society of Hematology (ASH) Annual Meeting...
05 déc. 2015 12h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies

Response Duration >2 Years Observed in a Patient with Plasma Cell Leukemia Findings Reported at American Society of Hematology (ASH) Annual Meeting 2015 SOUTH SAN FRANCISCO, Calif., Dec. 05,...
05 nov. 2015 16h05 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Third Quarter 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
05 nov. 2015 09h20 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio’s Collaborating Investigators to Present Data From Two Cellular Therapy Product Candidates at the American Society of Hematology (ASH) Annual Meeting 2015

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with...
29 oct. 2015 16h05 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Participation in Three Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients...
21 oct. 2015 06h30 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements

SOUTH SAN FRANCISCO, Calif. and BRISBANE, Australia, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful...
20 oct. 2015 06h30 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients...
14 oct. 2015 06h30 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio to Host Investor Day on October 21, 2015

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc., (Nasdaq:ATRA), today announced that the Company will host a live webcast in conjunction with its...
05 oct. 2015 07h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Bio’s PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients...

Page précédente